Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-LILRB monoclonal antibody ADA-011

A monoclonal antibody targeting the leukocyte immunoglobulin-like receptors B (LILRB) immune checkpoint receptor family, with potential immune checkpoint inhibitory, immunomodulating and antineoplastic activities. Upon administration, anti-LILRB monoclonal antibody ADA-011 targets, binds to and inhibits LILRB family members and their downstream signaling pathways. This may restore immune function and anti-tumor immune responses. The LILRB receptor family is a family of inhibitory immune checkpoint receptors that negatively regulates immune activation and plays an important role in immune evasion. Various LILRBs are expressed on certain types of cancer cells and play a key role in cancer development.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-leukocyte immunoglobulin-like receptors B monoclonal antibody ADA-011
Code name:ADA 011
ADA-011
ADA011
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search